Table 1 Baseline characteristics (n = 144)
Parameter | ME + LLD (n = 72) | ME (n = 72) | p-value |
|---|---|---|---|
Age | 66 (36–83) | 67.5 (34–90) | 0.246 |
Sex (male/female) | < 0.001 | ||
Male | 50 (69.4%) | 21 (29.1%) | |
Female | 22 (30.6%) | 51 (70.9%) | |
Body mass index | 23.0 (16.5–34.0) | 22.3 (16.6–32.7) | 0.334 |
ASA | 0.244 | ||
1–2 | 63 (87.5%) | 68 (94.4%) | |
3–4 | 9 (12.5%) | 4 (5.6%) | |
Serum CEA (ng/ml) | 4.3 (0.5–159.8) | 3.6 (0.5–65.8) | 0.132 |
Location | 0.557 | ||
Mid rectum | 15 (20.8%) | 19 (26.4%) | |
Low rectum | 57 (79.2%) | 53 (73.6%) | |
pT | 0.237 | ||
1–3 | 38 (52.7%) | 46 (63.8%) | |
4 | 34 (47.3%) | 26 (36.2%) | |
pN | 1.000 | ||
Negative | 30 (41.6%) | 29 (40.2%) | |
Positive | 42 (58.4%) | 43 (59.8%) | |
pStage | 1.000 | ||
II | 30 (41.6%) | 29 (40.2%) | |
III | 42 (58.4%) | 43 (59.8%) | |
pLLNM | 10 (13.8%) | – | – |
Neo-CRT | 5 (6.9%) | 0 | 0.058 |
Histological type | 1.000 | ||
Tubular adenocarcinoma | 67 (93.0%) | 66 (91.6%) | |
Other histological type | 5 (7.0%) | 6 (8.4%) | |
Tumor diameter (mm) | 50.0 (15–120) | 45.0 (3–95) | 0.293 |
Adjuvant CTx | 35 (48.6%) | 31 (43.0%) | 0.616 |